Clinical features and treatment outcomes of major depressive disorder with genital symptoms

[...]845 subjects were enrolled and randomized into the AGT (escitalopram or mirtazapine treatment) or TAU (treatment as usual) group, as described in previous publication. [...]325 patients (GS = 177, NGS = 148) with completed baseline information were included, of whom 243 participants completed the 2-week follow-up (GS = 136, NGS = 107), 208 completed the 4-week follow-up (GS = 115, NGS = 93), 176 completed the 6-week follow-up (GS = 99, NGS = 77), 136 completed the 8-week follow-up (GS = 73, NGS = 63), and 125 completed the 12-week follow-up (GS = 67, NGS = 58). [...]guilt, loss of weight, intelligence, cardiovascular symptoms, and respiratory symptoms on the HAM-D and HAM-A scales, and the mental condition and family relation item on the QoL scale were associated with genital symptoms in MDD patients. [...]the GS group exhibited higher HAM-D and DSSS scores after two weeks of treatment, as well as at the 4-week follow-up, indicating that those with genital symptoms would experience a slower recovery from depressive and somatic symptoms in the acute phase of treatment.